Helen B Ndagije

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/383993/publications.pdf

Version: 2024-02-01

1478505 1372567 14 115 10 6 citations h-index g-index papers 15 15 15 118 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Recognition and reporting of suspected adverse drug reactions by surveyed healthcare professionals in Uganda: key determinants. BMJ Open, 2014, 4, e005869.	1.9	26
2	Targeted Spontaneous Reporting of Suspected Renal Toxicity in Patients Undergoing Highly Active Anti-Retroviral Therapy in Two Public Health Facilities in Uganda. Drug Safety, 2015, 38, 395-408.	3.2	18
3	The Burden of Adverse Drug Reactions Due to Artemisinin-Based Antimalarial Treatment in Selected Ugandan Health Facilities: An Active Follow-Up Study. Drug Safety, 2018, 41, 753-765.	3.2	16
4	Medication Error Disclosure and Attitudes to Reporting by Healthcare Professionals in a Sub-Saharan African Setting: A Survey in Uganda. Drugs - Real World Outcomes, 2015, 2, 273-287.	1.6	12
5	Adverse Drug Reaction Onsets in Uganda's VigiBase®: Delayed International Visibility, Data Quality and Illustrative Signal Detection Analyses. Pharmaceutical Medicine, 2018, 32, 413-427.	1.9	12
6	Prescription of Levofloxacin and Moxifloxacin in Select Hospitals in Uganda: A Pilot Study to Assess Guideline Concordance. Antibiotics, 2020, 9, 439.	3.7	7
7	The effect of community dialogues and sensitization on patient reporting of adverse events in rural Uganda: Uncontrolled before-after study. PLoS ONE, 2019, 14, e0203721.	2.5	6
8	Rare, Serious, and Comprehensively Described Suspected Adverse Drug Reactions Reported by Surveyed Healthcare Professionals in Uganda. PLoS ONE, 2015, 10, e0123974.	2.5	4
9	Effectiveness of the Med Safety mobile application in improving adverse drug reaction reporting by healthcare professionals in Uganda: a protocol for a pragmatic cluster-randomised controlled trial. BMJ Open, 2022, 12, e061725.	1.9	4
10	Pharmacovigilance of suspected or confirmed therapeutic ineffectiveness of artemisinin-based combination therapy: extent, associated factors, challenges and solutions to reporting. Malaria Journal, 2020, 19, 389.	2.3	2
11	Evaluation of the Clinical Use of Ceftriaxone among In-Patients in Selected Health Facilities in Uganda. Antibiotics, 2021, 10, 779.	3.7	2
12	Healthcare professionals' perspective can guide post-marketing surveillance of artemisinin-based combination therapy in Uganda. Malaria Journal, 2020, 19, 63.	2.3	2
13	Drug Use Evaluation (DUE) of Ceftriaxone in Mubende Regional Referral Hospital, Uganda: A Cross-Sectional Survey. Journal of Pharmacy and Pharmacology Research, 2019, 03, .	0.3	2
14	Implementation of a peer support intervention to promote the detection, reporting and management of adverse drug reactions in people living with HIV in Uganda: a protocol for a quasi-experimental study. BMJ Open, 2022, 12, e056039.	1.9	2